New mRNA therapy takes on colorectal cancer in the liver
NCT ID NCT07610707
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new mRNA-based drug called YMN-A02 in 10 people with advanced colorectal cancer that has spread to the liver and has not responded to standard treatments. The drug is designed to help the immune system attack the cancer by producing a CTLA-4 antibody and a TGF-β trap. The main goal is to check safety and find the right dose, while also looking for any signs that the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YMN-A02 (an mRNA-based biologic that produces a CTLA-4 antibody and a TGF-β trap protein)
- What this could lead to
- If this early trial shows safety and hints of tumor shrinkage, it could point toward a new immunotherapy option for hard-to-treat colorectal cancer with liver spread.
- What could go wrong
- This is a very early Phase 1 trial with only 10 patients, so it is primarily testing safety, not effectiveness. The treatment may cause serious side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PMMR COLORECTAL CANCER WITH LIVER METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China